Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous: 50 mg) |
| Drug Class | Tissue plasminogen activator |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
Summary
- Tenecteplase (TNKase) is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
- According to a systematic review and meta-analysis, tenecteplase has similar safety and efficacy as alteplase for treatment of acute ischemic stroke (AIS). Both treatments resulted in comparable rates of modified Rankin Scale at 90 days.
- A Bayesian network meta-analysis suggests that tenecteplase 0.25 mg/kg may provide more benefit than alteplase 0.9 mg/kg in AIS treatment within 4.5 hours of symptom onset, despite an increased risk of symptomatic intracranial hemorrhage.
- Another study found that patients receiving tenecteplase might be associated with higher incidence of early neurologic improvement compared with those receiving alteplase, indicating potential benefits over the latter drug.
- Eight Systematic Reviews / Meta-Analyses were analyzed in total.
- Nonrandomized studies suggest that tenecteplase is potentially associated with improved functional outcomes compared to altepalse for treating AIS; however, further randomized trials are needed for validation.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| TNKase (tenecteplase) Prescribing Information. | 2023 | Roche Group, South San Francisco, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Management of acute ST segment elevation myocardial infarction (STEMI). | 2019 | National Heart Association of Malaysia |